HC Wainwright Forecasts PepGen’s Q1 Earnings (NASDAQ:PEPG)

PepGen, Inc. (NASDAQ:PEPG) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for PepGen in a report issued on Thursday, November 13th. HC Wainwright analyst A. Ghosh expects that the company will post earnings per share of ($0.52) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.52) EPS and Q4 2026 earnings at ($0.52) EPS.

PepGen (NASDAQ:PEPG) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11.

PEPG has been the subject of a number of other reports. Stifel Nicolaus raised their target price on PepGen from $9.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of PepGen in a research note on Wednesday, October 8th. Guggenheim reiterated a “buy” rating and issued a $6.00 price objective on shares of PepGen in a research note on Wednesday, September 24th. Finally, Wedbush boosted their target price on PepGen from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Thursday, September 25th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $10.00.

PepGen Trading Down 0.9%

PepGen stock traded down $0.05 during trading on Friday, hitting $4.84. The company had a trading volume of 58,176 shares, compared to its average volume of 1,897,136. PepGen has a 1-year low of $0.88 and a 1-year high of $6.85. The company’s 50 day simple moving average is $3.94 and its 200-day simple moving average is $2.25. The stock has a market cap of $158.88 million, a price-to-earnings ratio of -1.71 and a beta of 1.95.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PEPG. XTX Topco Ltd purchased a new position in PepGen in the 1st quarter valued at about $25,000. ADAR1 Capital Management LLC purchased a new stake in PepGen during the first quarter worth approximately $29,000. Rangeley Capital LLC raised its stake in shares of PepGen by 133.3% in the 2nd quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after acquiring an additional 20,000 shares during the period. Marshall Wace LLP acquired a new position in shares of PepGen during the second quarter worth about $44,000. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of PepGen in the second quarter valued at about $81,000. 58.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, major shareholder Science Enterprises Plc Oxford purchased 200,000 shares of the company’s stock in a transaction dated Tuesday, September 30th. The stock was acquired at an average price of $3.20 per share, for a total transaction of $640,000.00. Following the completion of the transaction, the insider directly owned 4,955,388 shares in the company, valued at $15,857,241.60. This represents a 4.21% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.20% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.